Tezepelumab-placebo, Tezspire 210 mg solution for injection in pre-filled syringe
D5241C00006
Phase 3 small_molecule active
Quick answer
Tezepelumab-placebo, Tezspire 210 mg solution for injection in pre-filled syringe for Chronic obstructive pulmonary disease (COPD) is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Chronic obstructive pulmonary disease (COPD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active